Larimar Therapeutics (LRMR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 41/100 (MEDIUM), 12.5 months cash
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 25.62% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Larimar (LRMR) Loses 22.7% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
- Larimar Therapeutics Strengthens Executive Leadership with Appointment of John Harlow as President and Chief Operating Officer
- Larimar Therapeutics (LRMR) Submits Initial Module of BLA For Nomlabofusp Therapy
- LRMR Stock Edges Up After Hours After Director Purchases Shares Worth About $167,000
- Here’s What Citi Thinks About Larimar Therapeutics (LRMR)
- LRMR Shares Hold Steady As Wall Street Optimism Offsets Drug Safety Concerns
- Larimar Therapeutics Shares Drop Following Clinical Update and Regulatory Filing (LRMR)
- Larimar's Rare Disease Push Just Hit A Key Inflection Point — What Investors Need To Know
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Larimar Therapeutics.
Full LRMR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.